Global Markets Direct’s, ‘HanAll Biopharma Co., Ltd. – Product Pipeline Review -2015′, provides an overview of the HanAll Biopharma Co., Ltd.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of HanAll Biopharma Co., Ltd.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• The report provides brief overview of HanAll Biopharma Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
• The report reviews current pipeline of HanAll Biopharma Co., Ltd.’s human therapeutic division and enlists all their major and minor projects
• The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
• Special feature on out-licensed and partnered product portfolio
• The report summarizes all the dormant and discontinued pipeline projects
• Latest company statement
• Latest news and deals relating to the HanAll Biopharma Co., Ltd.’s pipeline products

Reasons to buy

• Evaluate HanAll Biopharma Co., Ltd.’s strategic position with total access to detailed information on its product pipeline
• Assess the growth potential of HanAll Biopharma Co., Ltd. in its therapy areas of focus
• Identify new drug targets and therapeutic classes in the HanAll Biopharma Co., Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
• Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
• Develop strategic initiatives by understanding the focus areas of HanAll Biopharma Co., Ltd. and exploit collaboration and partnership opportunities
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Plan mergers and acquisitions effectively by identifying the most promising pipeline of HanAll Biopharma Co., Ltd.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Explore the dormant and discontinued projects of HanAll Biopharma Co., Ltd. and identify potential opportunities in those areas
• Avoid Intellectual Property Rights related issues

Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
HanAll Biopharma Co., Ltd. Snapshot 5
HanAll Biopharma Co., Ltd. Overview 5
Key Information 5
Key Facts 5
HanAll Biopharma Co., Ltd. - Research and Development Overview 6
Key Therapeutic Areas 6
HanAll Biopharma Co., Ltd. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Combination Treatment Modalities 11
HanAll Biopharma Co., Ltd. - Pipeline Products Glance 12
HanAll Biopharma Co., Ltd. - Late Stage Pipeline Products 12
Pre-Registration Products/Combination Treatment Modalities 12
Phase III Products/Combination Treatment Modalities 13
HanAll Biopharma Co., Ltd. - Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Phase I Products/Combination Treatment Modalities 15
HanAll Biopharma Co., Ltd. - Early Stage Pipeline Products 16
Preclinical Products/Combination Treatment Modalities 16
HanAll Biopharma Co., Ltd. - Drug Profiles 17
(atorvastatin calcium + losartan potassium) 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
(candesartan + amlodipine besylate) 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
(chlorthalidone + telmisartan) 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
cobamamide 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
HL-143 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
(metformin hydrochloride + candesartan) 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
HL-032 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
HL-036 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
HL-156FIB 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
HL-161 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
HL-176 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
HL-178 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
HanAll Biopharma Co., Ltd. - Pipeline Analysis 30
HanAll Biopharma Co., Ltd. - Pipeline Products by Target 30
HanAll Biopharma Co., Ltd. - Pipeline Products by Route of Administration 32
HanAll Biopharma Co., Ltd. - Pipeline Products by Molecule Type 33
HanAll Biopharma Co., Ltd. - Pipeline Products by Mechanism of Action 34
HanAll Biopharma Co., Ltd. - Recent Pipeline Updates 35
HanAll Biopharma Co., Ltd. - Dormant Projects 37
HanAll Biopharma Co., Ltd. - Discontinued Pipeline Products 40
Discontinued Pipeline Product Profiles 40
HL-015 40
HL-016 40
Loratadine ODT 40
HanAll Biopharma Co., Ltd. - Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
Appendix 42
Methodology 42
Coverage 42
Secondary Research 42
Primary Research 42
Expert Panel Validation 42
Contact Us 42
Disclaimer 43

List of Tables

HanAll Biopharma Co., Ltd., Key Information 5
HanAll Biopharma Co., Ltd., Key Facts 5
HanAll Biopharma Co., Ltd. - Pipeline by Indication, 2015 7
HanAll Biopharma Co., Ltd. - Pipeline by Stage of Development, 2015 9
HanAll Biopharma Co., Ltd. - Monotherapy Products in Pipeline, 2015 10
HanAll Biopharma Co., Ltd. - Combination Treatment Modalities in Pipeline, 2015 11
HanAll Biopharma Co., Ltd. - Pre-Registration, 2015 12
HanAll Biopharma Co., Ltd. - Phase III, 2015 13
HanAll Biopharma Co., Ltd. - Phase II, 2015 14
HanAll Biopharma Co., Ltd. - Phase I, 2015 15
HanAll Biopharma Co., Ltd. - Preclinical, 2015 16
HanAll Biopharma Co., Ltd. - Pipeline by Target, 2015 31
HanAll Biopharma Co., Ltd. - Pipeline by Route of Administration, 2015 32
HanAll Biopharma Co., Ltd. - Pipeline by Molecule Type, 2015 33
HanAll Biopharma Co., Ltd. - Pipeline Products by Mechanism of Action, 2015 34
HanAll Biopharma Co., Ltd. - Recent Pipeline Updates, 2015 35
HanAll Biopharma Co., Ltd. - Dormant Developmental Projects,2015 37
HanAll Biopharma Co., Ltd. - Discontinued Pipeline Products, 2015 40
HanAll Biopharma Co., Ltd., Other Locations 41

List of Figures

HanAll Biopharma Co., Ltd. - Pipeline by Top 10 Indication, 2015 7
HanAll Biopharma Co., Ltd. - Pipeline by Stage of Development, 2015 9
HanAll Biopharma Co., Ltd. - Monotherapy Products in Pipeline, 2015 10
HanAll Biopharma Co., Ltd. - Combination Treatment Modalities in Pipeline, 2015 11
HanAll Biopharma Co., Ltd. - Pipeline by Top 10 Target, 2015 30
HanAll Biopharma Co., Ltd. - Pipeline by Top 10 Route of Administration, 2015 32
HanAll Biopharma Co., Ltd. - Pipeline by Top 10 Molecule Type, 2015 33
HanAll Biopharma Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2015 34